|
Match
|
Document |
Document Title |
|
|
8168427 |
Monoclonal antibodies against claudin-18 for treatment of cancer
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric...
|
|
|
8153765 |
Anti-CD38 antibodies for the treatment of cancer
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of...
|
|
|
8105830 |
Polyspecific binding molecules and uses thereof
The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR)...
|
|
|
8101720 |
Immunoglobulin insertions, deletions and substitutions
An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc ...
|
|
|
8097703 |
CD19 antibodies and their uses
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19...
|
|
|
8088377 |
Human monoclonal antibodies against CD30
Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of...
|
|
|
8088383 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
8088896 |
Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38
The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods for using the same. These antibodies as well as the novel methods for using those...
|
|
|
8084585 |
Anti-ILT7 antibody
An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high...
|
|
|
8080242 |
Anti-HPA
The present invention relates to a monoclonal antibody selectively recognizing a human platelet alloantigen, a method for detecting the presence or absence of at least one human platelet...
|
|
|
8071367 |
Selecting, culturing and creating lineage committed hematopoietic stem cells
The present invention provides a method for selecting hematopoietic stem cells (HSCs) comprising providing an agent which binds to α9β1 integrin on the cell surface to a population of cells i...
|
|
|
8063187 |
Methods and compositions for inhibiting CD32B expressing cells
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and m...
|
|
|
7982011 |
Mutated anti-cd22 antibodies and immunoconjugates
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and...
|
|
|
7932357 |
FDF-03 S1 antigen-antibody complex
Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also...
|
|
|
7927591 |
Conformation specific antibodies
The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non...
|
|
|
7927595 |
Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodies
Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for...
|
|
|
7927596 |
Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptides
The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential...
|
|
|
7919595 |
Antibodies to interferon-like protein Zcyto21(IL29)
The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. ...
|
|
|
7915041 |
Hybridoma capable of producing anti-dectin-1 monoclonal antibody
A hybridoma capable of producing a monoclonal antibody against dectin-1, and a monoclonal antibody which specifically reacts with dectin-1.
|
|
|
7915004 |
Monoclonal antibodies, hybridomas, improved method for determining the protein PTX3 and kit for said determination
Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the...
|
|
|
7901685 |
Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion
This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of...
|
|
|
7902338 |
Anti-CD19 antibodies
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies,...
|
|
|
7888484 |
Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized...
|
|
|
7888478 |
Compositions and methods for the treatment of tumor of hematopoietic origin
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
|
|
|
7879984 |
Human antibodies to human CD20 and method of using thereof
A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing...
|
|
|
7850962 |
Human monoclonal antibodies against CD20
Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions...
|
|
|
7833530 |
Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both...
|
|
|
7829092 |
Recombinant anti-VLA4 antibody molecules
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific...
|
|
|
7829096 |
CD40L-specific monovalent polypeptides
The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential...
|
|
|
7825224 |
Product and method for treatment of conditions associated with receptor-desensitization
Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell...
|
|
|
7824684 |
Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies
This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind...
|
|
|
7824683 |
Methods for augmenting an immune response using anti-CD40 antibodies
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
|
|
|
7820170 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
7816500 |
Antibody SACK-1 that binds CD44 glycoforms
Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.
|
|
|
7812136 |
Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa
The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding...
|
|
|
7790166 |
Anti-CD40 antibodies capable of blocking B-cell activation
Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen...
|
|
|
7785590 |
Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ra1)
The present invention relates generally to antibodies that bind to the Interleukin-13 receptor α1 chain (IL-13Rα1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More p...
|
|
|
7786272 |
Antibodies to PRO352
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7744888 |
Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell...
|
|
|
7731966 |
Monoclonal antibodies against β3 integrins
Monoclonal antibodies prepared against platelet β3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using ...
|
|
|
7727525 |
Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.
|
|
|
7728115 |
Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of...
|
|
|
7718780 |
Preparation of monoclonal antibody to N-myc downstream regulated gene 2 and determination of NDRG2 using protein chip
The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a...
|
|
|
7667007 |
αvβ3-specific antibodies
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αvβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules e...
|
|
|
7666421 |
Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2
The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains...
|
|
|
7662926 |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
The present application describes antibodies that selectively bind human FcγRIIB, with little or no binding to other human FcγRs, e.g., human FcγRIIA. The invention also provides isolated bi...
|
|
|
7662928 |
Anti-FcRn antibodies for treatment of auto/allo immune conditions
Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or...
|
|
|
7662927 |
Antibodies to ZCYTO20 (IL-28A) and ZCYTO22 (IL-28B)
The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino ...
|
|
|
7655417 |
VCAM-1 specific monoclonal antibody
The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody...
|
|
|
7655230 |
Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective...
|